Study of low-density lipoprotein receptor regulation by oral (steroid) contraceptives: desogestrel, levonorgestrel and ethinyl estradiol in JEG-3 cell line and placental tissue

Contraception

Volumn 76, Issue 4, 2007, Pages 297-305

  Ramakrishnan, Gopalakrishnan ^a   Rana, Anita ^a   Das, Chandana ^a   Chandra, Nimai Chand ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Desogestrel; Ethinyl estradiol; LDL receptor; Levonorgestrel; Oral contraceptive

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; PROTEIN EXPRESSION;

CELL LINE, TUMOR; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; ETHINYL ESTRADIOL; HUMANS; LEVONORGESTREL; PLACENTA; RECEPTORS, LDL; UP-REGULATION;

EID: 34548827986     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.06.011     Document Type: Article

References (43)

1. Rosendaal F.R., Helmerhorst F.M., and Vandenbroucke J.P. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22 (2002) 201-210
2. Tanis B.C., and Rosendaal F.R. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors. Semin Vasc Med 3 1 (2003) 69-84
3. Martin K., Moride Y., Metge C., et al. Potential impact of oral contraceptive choice on myocardial infarction, mortality and deep vein thrombosis. J Fam Plann Reprod Health Care 31 (2005) 37-39
4. Drife J. Complication of oral contraceptions. In: Filshie M., and Guilleband J. (Eds). Contraception science and practice (1989), Butterworth & Co. Ltd., London 39-51
5. Stadel B.V. Oral contraceptives and cardiovascular disease. N Engl J Med 305 (1981) 612-618 [First of two parts]
6. Stadel B.V. Oral contraceptives and cardiovascular disease. N Engl J Med 305 (1981) 672-677 [Second of two parts]
7. Royal College of General Practitioners' Oral Contraceptive Study. Mortality among oral contraceptive users. Lancet 2 (1977) 727-731
8. Dalen J.E., and Hickler R.B. Oral contraceptives and cardiovascular disease. Am Heart J 101 (1981) 626-639
9. Inman W.H.W., Vessey M.P., Westerholm B., and Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 2 (1970) 303-309
10. Meade T.W., Greenberg G., and Thompson S.G. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg preparations. Br Med J 280 (1980) 1157-1161
11. Wahl P., Walden C., Knopp R., et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 308 (1983) 862-867
12. Foulon T., Payen N., Laporte F., et al. Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. Contraception 64 (2001) 11-16
13. Barkfeldt J., Virkkunen A., and Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on lipid metabolism. Contraception 64 (2001) 295-299
14. Endrikat J., Klipping C., Gerlinger C., et al. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 30 μg ethinyl estradiol and 75 μg gestodene on hemostatic variables, lipids and carbohydrate metabolism. Contraception 64 (2001) 235-241
15. Walldius G., and Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 259 (2006) 493-519
16. Buring J.E., O'Connor G.T., Goldhaber S.Z., et al. Decreased HDL2 and HDL3 cholesterol, apo A-I and apo A-II, and increased risk of myocardial infarction. Circulation 85 (1992) 22-29
17. Pischon T., Girman C.J., Sacks F.M., et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005) 3375-3383
18. Brown M.S., and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (1997) 331-340
19. Shea-Eaton W.K., Trinidad M.J., Lopez D., et al. Sterol regulatory element binding protein-1a regulation of the steroidogenic acute regulatory protein gene. Endocrinology 142 (2001) 1525-1533
20. Sudhof T.C., Goldstein J.L., Brown M.S., and Russell D.W. The LDL receptor gene: a mosaic of exons shared with different proteins. Science 228 (1985) 815-822
21. Satoru Y., Shirou I., Takeshi H., and Ken I. Effects of sex hormones on regulation of ABCG2 expression in the placental cell line BeWo. J Pharm Pharm Sci 9 (2006) 133-139
22. Edgar D.G. The chemical assay of progesterone. Biochem J 54 (1953) 50-55
23. Friedgood H.B., Garst J.B., and Haagen-Smit A.J. A new method for the separation of androgens from estrogens and the partition of estriol from the estrone-estradiol fraction with special reference to identification and quantitative microdetermination of estrogens by ultraviolet absorption spectrophotometry. J Biol Chem 174 (1948) 523-554
24. Nabi G., Seth A., Dinda A.K., and Gupta N.P. Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate. J Clin Pathol 57 (2004) 146-150
25. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955) 1345-1353
26. Zlatkis A., and Zak B. Study of a new cholesterol agent. Anal Biochem 29 (1969) 143-148
27. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
28. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
29. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76 (1979) 4350-4354
30. Gomes M.P., and Deitcher S.R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 164 (2004) 1965-1976
31. Smith N.L., Heckbert S.R., Lemaitre R.N., et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292 (2004) 1581-1587
32. De Stefano V., Rossi E., and Leone G. Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications. Semin Vasc Med 3 (2003) 47-60
33. Tanis B.C., Van Den Bosch M.A.A.J., Kemmeren J.M., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 345 (2001) 1787-1793
34. Dunn N., Thorogood M., Faragher B., et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 318 (1999) 1579-1583
35. Spitzer W.O., Lews M.A., Heinemann L.A., et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 312 (1996) 83-88
36. Sakai J., Duncan E.A., Rawson R.B., et al. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell 85 (1996) 1037-1046
37. Duncan E.A., Brown M.S., Goldstein J.L., and Sakai J. Cleavage site for sterol-regulated protease localized to a Leu-Ser bond in lumenal loop of sterol regulatory element binding protein-2. J Biol Chem 272 (1997) 12778-12785
38. Duncan E.A., Dave U.P., Sakai J., Goldstein J.L., and Brown M.S. Second-site cleavage in sterol regulatory element-binding protein occurs at transmembrane junction as determined by cysteine panning. J Biol Chem 273 (1998) 17801-17809
39. Walker A.M. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 57 (1998) 169-181
40. Lammers P., Blumenthal P.D., and Huggins G.R. Developments in contraception a comprehensive review of Desogen (desogestrel and ethinylestradiol). Contraception 57 (1998) 1S-27S
41. Spitzer W.O., Faith J.M., and MacRae K.D. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod 17 (2002) 2307-2314
42. Speroff L., and DeCherney A. Advisory board for the new progestins. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 81 (1993) 1034-1047
43. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346 (1995) 1582-1588